Contraindications to receiving CAPVAXIVE (PCV21) vaccine documented in Merck’s package insert include a previous severe allergic reaction or anaphylaxis to any component of PCV21 or any vaccine containing diphtheria toxoid.
Data on the administration of PCV21 to women who are pregnant is insufficient for Merck pharmaceuticals to provide any information on the risks of vaccination during pregnancy. There is no available data on the effects of PCV21 on the breast-fed infant and it is recommended that breastfeeding women carefully consider the possible risk of vaccination on the infant when considering this vaccine.
PCV21 is approved for adults 18 years of age and older. Persons under the age of 18 should not receive PCV21.
